BINOL-derived diphosphoramidites bearing unsymmetrical 1,2-diamine link and their application in asymmetric catalysis

New P,P-bidentate diastereomeric diphosphoramidite chiral ligands with mixed stereogenic elements and a C₁ backbone symmetry have been prepared from (S_a)- and (R_a)-1,1′-binaphthyl-2,2′-diol (BINOL) and (S)-N-benzyl-1-(pyrrolidin-2-yl)methanamine and are fully characterized. The use of these ligands provides up to 84% ee in the Pd-catalyzed asymmetric allylic substitution of (E)-1,3-diphenylallyl acetate and up to 95% ee in the Rh-catalyzed asymmetric hydrogenation of α-dehydrocarboxylic acid esters. The results indicate that the catalytic performance is highly affected by the axial chirality of the binaphthyl moieties of the ligand and the nature of the solvent.     

Non-singular space-times with a negative cosmological constant: V. Boson stars

We prove existence of large families of solutions of Einstein-complex scalar field equations with a negative cosmological constant, with a stationary or static metric and a time-periodic complex scalar field.     

Antibacterial and antibiofilm activity of nanochelating based silver nanoparticles against several nosocomial pathogens

The emergence of multi‐drug resistant (MDR) bacteria and dynamic pattern of infectious diseases demand to develop alternative and more effective therapeutic strategies. Silver nanoparticles (AgNPs) are among the most widely commercialized engineered nanomaterials, because of their unique properties and increasing use for various applications in nanomedicine. This study for the first time aimed to evaluate the antibacterial and antibiofilm activities of newly synthesized nanochelating based AgNPs against several Gram‐positive and ‐negative nosocomial pathogens. Nanochelating technology was used to design and synthesize the AgNPs. The cytotoxicity was tested in human cell line using the MTT assay. AgNPs minimal inhibitory concentration (MIC) was determined by standard broth microdilution. Antibiofilm activity was assayed by a microtiter‐plate screening method. The two synthesized AgNPs including AgNPs (A) with the size of about 20‐25 nm, and AgNPs (B) with 30‐35 nm were tested against Staphylococcus aureus, Staphylococcus epidermidis, Acinetobacter baumannii, and Pseudomonas aeruginosa. AgNPs exhibited higher antibacterial activity against Gram‐positive strains. AgNPs were found to significantly inhibit the biofilm formation of tested strains in concentration 0.01 to 10 mg/mL. AgNPs (A) showed significant effective antibiofilm activity compared to AgNPs (B). In summary, our results showed the promising antibacterial and antibiofilm activity of our new nanochelating based synthesized AgNPs against several nosocomial pathogens.     

Cobalt(II)-selective membrane electrode based on N,N′-di(thiazol-2-yl)formimidamide

A new PVC-membrane electrode for Co²⁺ ions based on N,N′-di(thiazol-2-yl)formimidamide (TF) as membrane carrier has been developed. The electrode resulted in Nernstian response (29.5?±?0.4?mV decade^?1) for Co²⁺ ion over a wide concentration range (2.5?×?10^?7 ?1.0?×?10^?1?M) with a detection limit of 6.1?×?10^?8?M. The sensor has a response time of about 10?s, and can be used for at least 2 months without observing any deviation from the Nernstain response. The electrode revealed good selectivity towards cobalt(II) ion over a wide variety of alkali, alkaline earth, transition, and heavy metal ions and could be used in the pH range 2.0–7.0. The electrode was used for determination of Co²⁺ in real samples.     

Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics

The appearance of pyrazolam in Internet shops selling ‘research chemicals’ in 2012 marked the beginning of designer benzodiazepines being sold as recreational drugs or ‘self medication’. With recent changes in national narcotics laws in many countries, where two uncontrolled benzodiazepines (phenazepam and etizolam), which were marketed by pharmaceutical companies in some countries, were scheduled, clandestine laboratories seem to turn to poorly characterized research drug candidates as legal substitutes. Following the appearance of pyrazolam, it comes with no surprise that recently, flubromazepam (7‐bromo‐5‐(2‐fluorophenyl)‐1,3‐dihydro‐2H‐1,4‐benzodiazepin‐2‐one), a second designer benzodiazepine, was offered on the market. In this article, this new compound was characterized using nuclear magnetic resonance, gas chromatography‐mass spectrometry (GC–MS), liquid chromatography–mass spectrometry (LC–MS/MS) and liquid chromatography quadrupole time‐of‐flight MS (LC–Q–ToF–MS). Additionally, a study was carried out, in which one of the authors consumed 4 mg of flubromazepam to gain preliminary data on the pharmacokinetic properties and the metabolism of this compound. For this purpose, serum as well as urine samples were collected for up to 31 days post‐ingestion and analyzed applying LC–MS/MS and LC–Q‐ToF‐MS techniques. On the basis of this study, flubromazepam appears to have an extremely long elimination half‐life of more than 100 h. One monohydroxylated compound and the debrominated compound could be identified as the predominant metabolites, the first allowing a detection of a consumption for up to 28 days post‐ingestion when analyzing urine samples in our case. Additionally, various immunochemical assays were evaluated, showing that the cross‐reactivity of the used assay seems not to be sufficient for safe detection of the applied dose in urine samples, bearing the risk that it could be misused in drug‐withdrawal settings or in other circumstances requiring regular drug testing. Furthermore, it may be used in drug‐facilitated crimes without being detected. Copyright © 2013 John Wiley & Sons, Ltd.     

Carbon monoxide isotope enrichment and separation by pressure swing adsorption

Simulations of three different 3-bed 3-step pressure swing adsorption (PSA) cycles were carried out to study the enrichment and recovery of ¹⁴CO from an isotopic mixture of ¹⁴CO, ¹³CO and ¹²CO using NaX zeolite. Each PSA cycle included feed pressurization/feed (FP/P), heavy reflux (HR) and countercurrent depressurization (CnD) steps; they differed only in the way the CnD step was carried out: PSA Cycle I was carried out under total reflux (i.e., with no ¹⁴CO heavy product production); PSA Cycle II was carried out with discontinuous ¹⁴CO heavy product production; and PSA Cycle III was carried out with continuous ¹⁴CO heavy product production. The effects of the CnD step valve coefficient (c _v ), heavy reflux ratio (R _R ), and cycle time (t _cyc ) on the PSA process performance were determined in terms of the ¹⁴CO enrichment, ¹⁴CO recovery and CO feed throughput. The results showed that there was essentially no limit to the extent of the ¹⁴CO enrichment, despite the inherently low ¹⁴CO/¹²CO (1.05) and ¹⁴CO/¹³CO (1.12) separation factors for these isotopes on NaX zeolite. Under total reflux an optimum c _v was found for the CnD step and ¹⁴CO enrichments as high as 152 were obtained. Using the optimum c _v under finite reflux, a ¹⁴CO enrichment approaching 20 and a ¹⁴CO recovery approaching 100 % were easily achieved with discontinuous (PSA Cycle II) or continuous (PSA Cycle III) ¹⁴CO heavy product production. There was essentially no difference in the performance of PSA Cycles II and III, a counterintuitive result. The ¹⁴CO enrichment and the ¹⁴CO recovery both increased with decreasing CO feed throughputs and higher R _R , which were always very close to unity.